Business
Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer
TARPON SPRINGS, Fla., July 7, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific Drug Response Predictor (DRP®) patient selection technology, today announced the appointment of Jeff Ervin as the Company’s new Chief Financial Officer (CFO). He succeeds Alexande
About this update from Allarity Therapeutics, Inc.
[{"type":"image","alt":"Allarity Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Allarity Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":138,"url":"https://media.zenfs.com/en/globenewswire.com/16a0c0de99db65c057c520e53af4186e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/H2n2B7OUZZNZTe8771hvug--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/16a0c0de99db65c057c520e53af4186e","width":300,"height":138}},"lazy":false},{"type":"text","content":" ","length":1,"tagName":"p"},{"type":"text","content":"TARPON SPRINGS, Fla., July 7, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific Drug Response Predictor (DRP®) patient selection technology, today announced the appointment of Jeff Ervin as the Company’s new Chief Financial Officer (CFO). He succeeds Alexander Epshinsky, who will remain engaged with the Company during a transition period.","length":581,"tagName":"p"},{"type":"text","content":"Mr. Ervin brings nearly two decades of executive leadership experience across the healthcare, biotech, and other sectors. He most recently served as Co-Chief Financial Officer at NYSE-listed DayDayCook and was previously Chief Executive Officer of NASDAQ-listed IMAC Holdings, where he led the company through a successful public listing and national expansion. Earlier in his career, he held a senior finance role at Medx Publishing. Mr. Ervin currently serves on the board of directors of NASDAQ-listed Cingulate Inc., a biopharmaceutical company focused on the development of new product candidates for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).","length":671,"tagName":"p"},{"type":"text","content":"“We are pleased to welcome Jeff to the Allarity executive team. His strong track record in public company leadership and financial management aligns well with our mission to accelerate the clinical development of stenoparib,” said Thomas Jensen, Chief Executive Officer of Allarity Therapeutics. “Jeff’s extensive experience will be highly valuable in supporting a sustainable financial strategy and...